New UK health research strategy report is welcomed by pharmaceutical industry

13 February 2006

Best Research for Best Health, the new research strategy issued by the UK's Department of Health, is intended to streamline the governance of R&D in the National Health Service and develop clinical research expertise. The British Medical Journal reports that the two main planks of reform involve the centralization of funding and the establishment of the National Institute for Health Research, the National School for Primary Care Research and NHS research networks across England. The NHS expects to spend over L650.0 million ($1.14 billion) to implement the strategy.

"Bureaucracy-busting" is a key element

In a recent interview in the Scientist, a spokesman for the Department of Health described "bureaucracy-busting" as one of the key points of the new strategy: "we want to make it easier for people to do research using patient records." One measure being introduced to further this aim is the research passport, which will end the repetition of credential checks by different health authorities. A national expert advice line will also operate on a round-the-clock basis to provide expert advise on interpreting the law.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight